



Published in final edited form as:

CNS Neurol Disord Drug Targets. 2009 December ; 8(6): 403–421.

The Endocannabinoid System and Pain

Josée Guindon and Andrea G. Hohmann*

Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Athens, GA 30602-3013

Abstract

The therapeutic potential of cannabinoids has been the topic of extensive investigation following the discovery of cannabinoid receptors and their endogenous ligands. Cannabinoid receptors and their endogenous ligands are present at supraspinal, spinal and peripheral levels. Cannabinoids suppress behavioral responses to noxious stimulation and suppress nociceptive processing through activation of cannabinoid CB₁ and CB₂ receptor subtypes. Endocannabinoids, the brain's own cannabis-like substances, share the same molecular target as Δ^9 -tetrahydrocannabinol, the main psychoactive component in cannabis. Endocannabinoids serve as synaptic circuit breakers and regulate multiple physiological and pathological conditions, e.g. regulation of food intake, immunomodulation, inflammation, analgesia, cancer, addictive behavior, epilepsy and others. This review will focus on uncovering the roles of anandamide (AEA) and 2-arachidonoylglycerol (2-AG), the two best characterized endocannabinoids identified to date, in controlling nociceptive responding. The roles of AEA and 2-AG, released under physiological conditions, in modulating nociceptive responding at different levels of the neuraxis will be emphasized in this review. Effects of modulation of endocannabinoid levels through inhibition of endocannabinoid hydrolysis and uptake is also compared with effects of exogenous administration of synthetic endocannabinoids in acute, inflammatory and neuropathic pain models. Finally, the therapeutic potential of the endocannabinoid signaling system is discussed in the context of identifying novel pharmacotherapies for the treatment of pain.

Keywords

anandamide; 2-arachidonoyl glycerol; FAAH; MGL; endocannabinoid transporter; analgesia; inflammatory; neuropathic pain

INTRODUCTION

Cannabis has been used for more than twelve thousand years and for many different purposes (i.e. fiber, medicinal, recreational). However, the endocannabinoid signaling system has only recently been the focus of medical research and considered a potential therapeutic target [1–3]. Endocannabinoids mimic the pharmacological actions of the psychoactive principle of marijuana, Δ^9 -tetrahydrocannabinol (Δ^9 -THC) [4]. Endocannabinoids are endogenous lipid-signaling molecules. They are generated in the cell membrane from phospholipid precursors and possess cannabimimetic properties because they bind and activate one or more cannabinoid receptor subtypes [5,6]. Endocannabinoids are implicated in different physiological and

*Author for Correspondence: Andrea G. Hohmann, Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Athens, GA 30602-3013, Tel: 706-542-2252, Fax: 706-542-3275, ahohmann@uga.edu.

CONFLICT OF INTEREST

The authors state no conflict of interest.

pathological functions (regulation of food intake, immunomodulation, inflammation, analgesia, cancer, addictive behavior, epilepsy and others) [2,7]. The two best-studied endocannabinoids isolated to date are arachidonylethanolamine (anandamide or AEA) and 2-arachidonoylglycerol (2-AG). AEA is hydrolyzed by the enzyme fatty-acid amide hydrolase (FAAH) whereas 2-AG is degraded by the enzyme monoacylglycerol lipase (MGL) [7,8]. The main goal of this review will be to uncover the role of AEA and 2-AG in pain modulation. This will be accomplished by reviewing studies examining mobilization of endocannabinoids under physiological conditions or by using pharmacological tools that inhibit their uptake or degradation. This review will also consider studies employing exogenous administration of synthetic endocannabinoids in combination with other pharmacological approaches aimed at regulating their uptake or degradation. The overall goal is to understand the physiological role of the endogenous ligands at different levels of the pain pathway and in different models of pathological pain.

CANNABINOID RECEPTOR PHARMACOLOGY

Cannabinoids produce their effects through the activation of distinct G protein-coupled receptors identified as the cannabinoid CB₁ [9,10] and CB₂ receptors [11]. Cannabinoid CB₁ and CB₂ receptors are members of the superfamily of seven-transmembrane-spanning G protein-coupled receptors and share 44 % identity at the protein level [11,12]. Similarity increases to 68 % when only the transmembrane region is considered [11,12]. Activation of both cannabinoid receptor subtypes inhibits adenylate cyclase activity by coupling to the α -subunit of the G protein of the G_{i/o} family (G_{i 1, 2 and 3}, and G_{o 1 and 2}) [13]. In contrast to CB₂ receptor activation, CB₁ receptor activation modulates calcium or potassium conductance [14,15], properties linked to the suppression of neuronal excitability and neurotransmitter release. However, activation of MAPK and Krox-24 expression presumably through the activation of G-protein $\beta\gamma$ subunits is another signalling mechanism recruited by both CB₁ and CB₂ receptors [16,17]. Furthermore, CB₁ receptor activation can inhibit type 5-HT₃ ion channels [18], modulate the production of nitric oxide [for review see 19,20], alter sodium channel conductance [21] and activate the Na⁺/H⁺ exchanger [22]. Signaling mechanisms engaged by activation of CB₁ and CB₂ receptors have been recently reviewed [13,23].

Cannabinoid CB₁ receptors are found mainly in the CNS and, to a lesser extent, in certain peripheral tissues [24]. At the peripheral level, they are localized in adrenal gland, adipose tissue, heart, liver, lung, prostate, uterus, ovary, testis, bone marrow, thymus, tonsils and presynaptic nerve terminals [12,20,25–27]. Within the brain, they are found in the cerebral cortex, hippocampus (with highest concentrations in the dentate gyrus), amygdala, basal ganglia, substantia nigra pars reticulata, internal and external segment of the globus pallidus and cerebellum (molecular layer) [15,20,24]. More significantly for the purposes of the present review, they are found at central and peripheral levels of the pain pathways [28–32]. The distribution of cannabinoid receptors provides an anatomical basis for the analgesic effects of the cannabinoids. Activation of presynaptic CB₁ receptors in different brain regions or on primary afferents inhibits the release of neurotransmitters by decreasing calcium conductance and by increasing the potassium conductance [26].

CB₂ receptors are primarily localized to cells of the immune system. CB₂ receptors are mainly found in the spleen, tonsils and thymus, tissues responsible for immune cell production and regulation [11,12,15]. These immune cells include mast cells, B cells, T4 and T8 cells, microglial cells, macrophages, natural killer cells and, to a lesser extent, monocytes and polymorphonuclear neutrophils [12,15,33]. Previous reports suggested that CB₂ receptors were absent in neurons of the central nervous system (CNS) [11,34]. However, recent studies suggest that they are found in the brain, on dorsal root ganglia, in the lumbar spinal cord, on sensory neurons, on microglia as well as in peripheral tissues [35,36].

A better understanding of the role of cannabinoid receptors in different physiological processes has been obtained through research employing pharmacological and genetic tools such as competitive antagonists and knockout mice with disrupted CB₁ [37,38] and/or CB₂ genes [39,40]. Pharmacological evidence also supports the existence of one or more additional receptors for cannabinoids distinct from CB₁ and CB₂ receptors (reviewed in [41,42]). Of particular recent interest are the GPR55 receptor [43–45] and GPR3, GPR6 and GPR12 which are sphingosine-1-phosphate lipid receptors [46–48]. More work is necessary to determine the connection of novel receptor subtypes such as GPR55 to the endocannabinoid system using more specific compounds and genetic tools.

ENDOCANNABINOIDS

The discovery of AEA [49], the first endocannabinoid isolated from brain, was followed a few years later by the identification of 2-AG [50,51]. Since then, several putative endocannabinoids have been isolated which include noladin ether [52], virodhamine [53] and N-arachidonoyldopamine (NADA) [54,55]. Much less information is known about the endocannabinoid-like properties of these latter putative endogenous ligands (see [56] for a review). Indeed, elucidation of the endogenous function of these compounds in different physiological processes and their precise mechanisms of action requires further investigation [57]. Here, we will consider the roles of different cannabinoid receptors, different endocannabinoids and the machinery responsible for their synthesis and degradation. In some cases, functions of the endocannabinoid system are surmised following pharmacological inhibition of endocannabinoid deactivation. Thus, FAAH and MGL inhibitors increase endocannabinoid accumulation (AEA and 2-AG, respectively) by inhibiting hydrolysis of fatty-acid amides and monoacylglycerols; these enzymes have multiple substrates. Both AEA and 2-AG are derivatives of arachidonic acid and bind to cannabinoid CB₁ and CB₂ receptors, although with different affinities and efficacies [58]. However, the variable affinity for cannabinoid receptors may be due, in part, to the existence of distinct binding sites for the different ligands on cannabinoid receptors, as documented by molecular modeling studies [59].

SYNTHESIS AND RELEASE OF AEA AND 2-AG

Endocannabinoids are produced on demand either by activity-dependent or receptor-stimulated cleavage of membrane phospholipid precursors. Endocannabinoids can be released immediately from cells after their production since they are highly lipophilic and thus are poorly suited for storage (for review see [8,60,61]). Endocannabinoid signaling is regulated by synthesis, release, uptake and degradation. Membrane depolarization, increases in intracellular calcium levels and receptor stimulation can all activate enzymatic processes leading to the cleavage of membrane phospholipids precursors and subsequent synthesis of endocannabinoids (see [8,60,61] for a review). Different enzymes are implicated in the synthesis of AEA and 2-AG. AEA biosynthesis was originally believed to occur from enzymatic cleavage of a phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine (NAPE). NAPE is synthesized by the enzymatic transfer of arachidonic acid in the sn-1 position of a phosphatidylcholine to the amide group of a phosphatidylethanolamine under the supervision of the calcium-independent N-acyl-transferase (NAT) [62]. NAPE is then hydrolyzed to AEA by a specific phospholipase D (NAPE-PLD) which has recently been cloned and molecularly characterized [8,63–65]. However, NAPE-PLD knockout mice show no deficit in AEA production, a finding which questions the role of this enzyme in anandamide biosynthesis [66]. Thus, multiple enzymatic pathways may be involved in the biosynthesis of anandamide and NAPE-PLD is unlikely to exclusively control its' biosynthesis [66,67]. 2-AG is synthesized in a two step process. First, the 2-AG precursor diacylglycerol (DAG) is formed from enzymatic cleavage of membrane phospholipid precursors by the enzyme phospholipase

C (PLC) (for review see [68,69]). DAG is subsequently hydrolyzed by a diacylglycerol lipase (DAGL) selective for the sn-1 position to generate 2-AG [8,68,70,71]. A detailed review of these processes is available [7,60,61] (see Fig. 1). Subsequent to their on-demand synthesis, endocannabinoids may activate cannabinoid receptors following their release into the extracellular space or their movement directly into the cell membrane [72]. AEA preferentially binds to CB₁ receptors *in vitro*, and exhibits low affinity for the transient receptor potential vanilloid 1 (TRPV1) [73–76]. 2-AG is known to activate both CB₁ and CB₂ receptors [50, 51]. This compound is found in the brain in concentrations 170-fold higher than those of anandamide [77]. A role for endogenous 2-AG in pain modulation has only recently been described [78,79].

In addition to activating metabotropic CB₁ receptors, AEA can also activate ionotropic TRPV1 receptors as an endovanilloid. TRPV1 receptors are expressed in nociceptive sensory neurons and can detect/respond to noxious mechanical, thermal (i.e. heat) and chemical (i.e. capsaicin) stimuli [73,75,80–83]. Capsaicin and AEA share the same binding site [84], but AEA must be found at high concentrations to activate TRPV1 receptors. Activation of TRPV1 receptors increases intracellular levels of cations such as Ca²⁺ and depolarizes the cell; these effects can also liberate calcitonin gene-related peptide (CGRP) and substance P to produce vasodilatation [73]. At high concentrations, AEA can thus exert opposing effects through activation of cannabinoid and TRPV1 receptors, respectively. A functional relationship exists between TRPV1 and CB₁ receptors in dorsal root ganglia [85], spinal cord and brain [86] and wherever these two receptors may be co-expressed in the same cell. Antagonists of TRPV1 receptors are implicated in anxiolytic effects in the brain [82]. Peripheral and central TRPV1 receptors therefore remain a viable therapeutic target.

UPTAKE OF ENDOCANNABINOIDS

Reuptake of endocannabinoids, and most notably anandamide, in the synaptic space may be facilitated by a transporter that has yet to be molecularly cloned. Pharmacological inhibitors for endocannabinoid transport have nonetheless been developed (AM404, VDM11, and others) [7,74,87,88]. AEA may accumulate in neurons and other cells by facilitated diffusion rather than employing a specific transport mechanism [89,90]. This process is saturable, temperature-dependent, does not require ATP and is driven by a transmembrane concentration gradient. The existence of a specific endocannabinoid transporter remains controversial, and new discoveries are necessary to establish beyond doubt the mechanism of endocannabinoid transport [90–93]. However, it is noteworthy that AEA uptake is selectively inhibited by a variety of pharmacological agents, consistent with the existence of a saturable component in the transport of anandamide [87,94–96] (see Fig. 1).

Since endocannabinoids are produced on demand and can be released immediately from cells, they can regulate synaptic transmission, both excitatory and inhibitory. In the CNS, endocannabinoids act as neurotransmitters. Endocannabinoids are released from depolarized postsynaptic neurons and travel to presynaptic terminals where they activate CB₁ receptors through a retrograde signaling mechanism [97–100] (see Fig. 1). The general effect is a decrease in the release of neurotransmitters such as GABA (γ -amino butyric acid) or glutamate. This retrograde signaling mechanism suggests an important modulatory role for endocannabinoids in controlling neuronal excitability and maintaining homeostasis [101].

DEGRADATION OF AEA AND 2-AG

Endocannabinoid signaling is limited by efficient degradation processes involving enzymatic hydrolysis mediated by specific intracellular enzymes. The enzymes which degrade endocannabinoids are quite well characterized and include fatty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) ([60,61], for a review). Inhibitors for FAAH (AM374,

URB597, URB532 and others) or MGL (URB602, OMDM169, JZL184 and Compound 11) enzymes have been described ([102]; see [7,103] for a review), although selectivity of some agents may vary considerably. FAAH hydrolyzes AEA and related compounds [103–105] whereas MGL metabolizes 2-AG [106,107]. FAAH, a membrane bound enzyme, hydrolyzes AEA in neurons and astrocytes into breakdown products arachidonic acid and ethanolamine [104,108]. The distribution of FAAH in organs of the rat has been described in detail; its activity is highest in the liver followed by the small intestine, brain, and testis (see [109] for a review). Immunohistochemical studies have mapped the distribution of FAAH in the brain. FAAH is found in the termination zone of the spinothalamic tract in the ventral posterior lateral nucleus of the thalamus [110–112]. This pathway is implicated in the transmission of nociceptive information to the brain (for review see [113]). FAAH has also been found in Lissauer's tract, in neurons of the superficial dorsal horn of the spinal cord and in dorsal root ganglion cells. Although FAAH can hydrolyze 2-AG *in vitro* [114], MGL is the predominant enzyme which controls 2-AG hydrolysis. MGL, a serine hydrolase, hydrolyzes 2-AG into breakdown products (arachidonic acid and glycerol). MGL is located on presynaptic [60,78,106] whereas FAAH is found on post-synaptic [60,103] neurons. Northern blot, immunohistochemical and *in situ* hybridization techniques have demonstrated that MGL, a presynaptic enzyme, is heterogeneously distributed in the rat brain with the highest levels observed in regions expressing CB₁ receptors, such as the cortex, thalamus, hippocampus and cerebellum [106]. MGL is localized exclusively to axon terminals, where it colocalizes with CB₁ [115]. By contrast, FAAH is a postsynaptic enzyme and may regulate AEA levels near sites of synthesis [60,103]. Although the biosynthesis and metabolism of AEA and 2-AG have been simplified here to maintain the focus of this review, it is important to mention that, in addition to hydrolysis, alternative metabolic pathways exist [67,116–118]. For example, in addition to undergoing hydrolysis, endocannabinoids undergo oxidative metabolism, through which they are transformed into other biologically active mediators [119]. Indeed, there is evidence for the metabolism of AEA and 2-AG by cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 enzymes, further adding to the complexity of endocannabinoid signalling mechanisms [116,117,120,121].

ENDOCANNABINOIDS IN PAIN PATHWAYS

Cannabinoid receptors, endocannabinoids, and enzymes controlling their synthesis and degradation are localized to multiple levels of the neuraxis, from the periphery to the CNS ([122]; for review see [123]). The discovery of the endocannabinoid system, the availability of antagonists for cannabinoid receptors (CB₁ and CB₂) and the generation of knockout mice lacking CB₁ and/or CB₂ and FAAH have spurred research in this growing field. Sites of action for endocannabinoids in suppressing pain were initially suggested by studies employing synthetic cannabinoids targeted at CB₁ and/or CB₂ receptors. These studies have been recently reviewed [123–126].

SUPRASPINAL LEVEL

The antinociceptive [127] and electrophysiological [128] effects produced by the systemic administration of cannabinoids are attenuated following spinal transection. These studies implicate an important role for supraspinal sites in contributing to cannabinoid analgesic action. Direct support for supraspinal sites of cannabinoid analgesic action was derived from studies injecting synthetic cannabinoid agonists intraventricularly and locally into various brain regions (for review see [126]). Structures targeted include the periaqueductal gray (PAG) [129,130], thalamus [131], rostral ventromedial medulla (RVM) [132,133] and amygdala [134,135], among others. These studies have permitted the identification of brain regions responsible for the antinociceptive properties of cannabinoids. Activation of these sites by endocannabinoids may, therefore, produce antinociception under physiological conditions.

Neurophysiological studies by Walker's laboratory first documented that cannabinoids suppress nociceptive processing ([131,132,136]; see [126] for a review). Cannabinoids, administered systemically, suppress activity of nociceptive neurons in the spinal dorsal horn [136] and ventralposterior lateral nucleus of the thalamus, without altering the activity of purely nonnociceptive neurons [131]. Importantly, these neurophysiological effects correlate highly with the antinociceptive effects of cannabinoids, and cannot be attributed to the motor effects of the same compounds [131].

Walker's group first identified a role for endogenous AEA, released under physiological conditions, in pain modulation [137]. Electrical stimulation of the dorsolateral PAG produced antinociception in the tail-flick test and mobilized endogenous AEA, as measured by microdialysis. Importantly, this stimulation-produced analgesia was blocked by the CB₁ antagonist SR141716A, demonstrating mediation by CB₁. Intraplantar administration of formalin was also shown to increase levels of endogenous AEA in the dorsolateral PAG. Thus, noxious stimulation may produce endocannabinoid mobilization [137]. Exposure to an environmental stressor (brief continuous footshock) also produces endocannabinoid-mediated stress-induced analgesia that is associated with mobilization of endogenous 2-AG and anandamide [78]. Endocannabinoid mobilization was most pronounced in dorsal midbrain fragments containing the intact PAG [78]. Endocannabinoid-mediated stress-induced analgesia is blocked by CB₁ but not by CB₂ antagonists and is insensitive to blockade by opioid (i.e. with naltexone) and TRPV1 (i.e. with capsazepine) antagonists [78,138]. Moreover, 2-AG mobilization in the PAG correlates highly with endocannabinoid-mediated stress antinociception [139]. These observations are also consistent with the ability of systemic and locally administered FAAH inhibitors (e.g. URB597, arachidonoylserotonin), endocannabinoid uptake inhibitors (e.g. VDM11) and locally administered MGL inhibitors (URB602) to enhance endocannabinoid-mediated stress antinociception through a CB₁-dependent mechanism [78,79,138]. These effects were all observed at doses that do not alter basal nociceptive thresholds. In the case of URB602, which is not appropriate for systemic use as a selective MGL inhibitor, biochemical studies confirmed that URB602, injected into the PAG, increased levels of 2-AG selectively without altering levels of AEA [78]. These studies collectively suggest a functional role for endogenous AEA and 2-AG in suppressing pain under physiological conditions.

Exogenous cannabinoids also modulate activity of ON and OFF cells in the rostral ventromedial medulla; here, inactivation of the RVM suppresses exogenous cannabinoid antinociception [133]. Pharmacological inactivation of the RVM also suppresses endocannabinoid-mediated analgesia in a rodent model of stress-induced analgesia [138]. Endocannabinoid-mediated stress-induced analgesia is also enhanced in a CB₁-dependent manner by intra-RVM administration of a FAAH inhibitor, administered at doses that do not alter the basal nociceptive threshold [138]. These studies support a role for endogenous AEA in the RVM in endocannabinoid-mediated analgesia, although a role for 2-AG has not been assessed.

Endocannabinoid levels are altered following nerve injury in specific brain regions implicated in cannabinoid antinociceptive mechanisms. For example, injury of the sciatic nerve increases AEA and 2-AG levels in the PAG and RVM [140], structures implicated in both the descending modulation and the descending facilitation of pain (see [113] for review). AEA levels were also increased in the dorsal raphe following chronic constriction injury (CCI) [140,141].

Systemic administration of inhibitors of endocannabinoid uptake (VDM-11, OMDM-2, UCM-707 and LY2318912) increases AEA and/or 2-AG levels in brain [93,142]. Interestingly, FAAH inhibition by N-arachidonoyl-serotonin (AA-5-HT) was shown to increase brain levels

of AEA and 2-AG [142]. These studies suggest that inhibitors of endocannabinoid uptake and deactivation show therapeutic potential for increasing endocannabinoid levels.

SPINAL LEVEL

Intrathecal administration of cannabinoids produces antinociception [143–145], and suppresses nociceptive neuronal activity [146]. These studies initially documented the existence of spinal sites of cannabinoid antinociceptive actions. Indeed, behavioral [143,145], electrophysiological [146–148] and neurochemical [128,149] studies have demonstrated that cannabinoids act at the spinal level to modulate pain. Mixed cannabinoid agonists such as levonantradol [145], WIN55,212-2 [150] and CP,55,940 [151], at the spinal level, produce CB₁-mediated antinociceptive effects. Moreover, cannabinoids suppress C-fiber-evoked responses of dorsal horn neurons recorded in normal, inflamed and nerve injured rats [152–155]. Furthermore, these data are consistent with the ability of cannabinoids to suppress Fos protein expression, a neurochemical marker of sustained neuronal activation, in different animal models of persistent pain through CB₁ and CB₂-specific mechanisms [128,156–159]. Cannabinoid receptors have been demonstrated on primary afferents neurons at pre- and post-synaptic sites in the spinal cord using receptor binding and quantitative autoradiography [160,161]. In the dorsal horn of the spinal cord, CB₁ receptors have been found on interneurons [29] and on astrocytes [162].

Upregulation of cannabinoid receptors is also observed in the spinal cord following nerve injury [150,163], suggesting that both endocannabinoids and their receptors are regulated under conditions of injury. Exposure to an acute environmental stressor increases 2-AG, but not anandamide, accumulation in the lumbar spinal cord; 2-AG accumulation in the spinal cord correlates highly with the appearance of stress antinociception [79]. Intrathecal administration of inhibitors of both FAAH (URB597/AA5-HT) and MGL-preferring (URB602) also enhance endocannabinoid-mediated stress-induced analgesia through a CB₁-dependent mechanism.

AEA and 2-AG are also increased in the spinal cord following induction of a neuropathic pain state produced by CCI of the sciatic nerve [140]. The endocannabinoid system is similarly modulated in response to a spinal cord contusion in rats [164]. The early stages are marked by increases in AEA levels, upregulation of the synthetic enzyme NAPE-PLD, and downregulation of the degradative enzyme FAAH. The delayed stages are marked by increases in 2-AG, a marked upregulation of the 2-AG synthesizing enzyme DAGL- α (i.e. in neurons, astrocytes and immune infiltrates), and a moderate increase in levels of the degradative enzyme MGL [164]. In this study, CB₁ receptors were expressed in neurons, oligodendrocytes, and astrocytes, whereas CB₂ receptors were strongly upregulated after the lesion and expressed mainly in immune infiltrates and astrocytes [164]. These studies highlight the importance of the endocannabinoid system as a potential therapeutic target for treatment of both spinal cord injury and neuropathic pain.

PERIPHERAL LEVEL

Peripheral antinociceptive actions of cannabinoids have been demonstrated in numerous animal pain models (for review see [123–125]). Harnessing these mechanisms shows considerable promise for separating the therapeutic effects of cannabinoids from unwanted CNS side-effects. Cannabinoid receptors are synthesized in dorsal root ganglion (DRG) cells, which are the source of primary afferent input to the spinal cord [30,31,85,165–167]. These afferent nerve fibers transmit information about sensory stimulation to the spinal cord, thereby enabling communication between the periphery and specific areas of the CNS that contribute to pain perception [168,169]. Following the induction of neuropathy (by spinal nerve ligation), cannabinoid receptors and their endogenous ligands (AEA and 2-AG) are increased in the DRG on the ipsilateral side of the injury [170]. Cannabinoid CB₁ [30,31,85,162] and CB₂ receptors

[165,167] are also found in the DRG. DRG cells synthesize cannabinoid receptors, and transport them to peripheral terminals of primary afferents [30,31]. Multiple approaches support the presence of cannabinoid receptors on primary afferent neurons [85,166,171]. CB₁ and CB₂ receptors are found in large myelinated and small unmyelinated human cutaneous nerve fibers [166]. Both cannabinoid receptor subtypes have also been found in different layers of the skin, and in some adnexal structures (sweat glands, sebaceous cells and others) which may contribute to peripheral antinociceptive actions [166,172–175]. Endocannabinoid levels and FAAH activity have also been measured in rodent paw skin [176–179]. AEA is observed in paw tissue [177–178] whereas a decrease in FAAH activity is observed in the inflamed paw following carrageenan-induced inflammation [179]. In the formalin model, 2-AG hydrolysis inhibitor, OMDM169, increased levels of 2-AG, but not AEA, in the ipsilateral paw [180]. However, Beaulieu and collaborators did not find an increase in AEA and 2-AG levels in the formalin test, measured 2 h after formalin injection when pain behavior has subsided [176]. In a model of bone cancer pain, intraplantar administration of exogenous AEA or the FAAH inhibitor URB597 increased the local level of AEA [181]. These studies suggest that manipulation of peripheral endocannabinoids may be promising strategy for the management of pain.

MODULATION OF THE ENDOCANNABINOID SYSTEM IN ANIMAL MODELS

Studies evaluating the presence of hypersensitivity to pain (hyperalgesia) following pharmacological blockade of CB₁ receptors provided early physiological support for the hypothesis that endocannabinoids suppress pain. Hyperalgesia has been observed in the hotplate test following intrathecal administration of the CB₁ antagonist/inverse agonist SR141716A, and these effects are mimicked by CB₁ antisense knockdown at the spinal level [182,183]. Pharmacological blockade of CB₁ receptors with SR141716A has also been reported to produce hyperalgesia in the formalin test [177,184]. However, these findings have not been observed by all investigators [176], suggesting that differences in the level of endogenous analgesic tone may contribute to differences between the studies (see [126] for review). Moreover, the inverse agonist properties of SR141716A complicate interpretation of studies attempting to unmask tonic endocannabinoid activity using competitive antagonists.

Therefore, documentation of intrinsic effects of endocannabinoids released under physiological conditions is critical for understanding the functional roles of endocannabinoids in nociceptive processing. As described above, studies employing stimulation-produced analgesia and stress-induced analgesia provide direct support for the hypothesis that endogenous AEA and 2-AG suppress pain through a CB₁-dependent mechanism. In these studies, the tail-flick test was used to quantify the impact of electrical brain stimulation or exposure to footshock stress on antinociception. Thus, it is important to emphasize that treatment with CB₁ antagonists [79,128,137,138,160] or modulators of endocannabinoid transport or deactivation [79,128,138,160] lacked intrinsic effects in the tail-flick test in the absence of a stimulus to trigger endocannabinoid mobilization (i.e. brain stimulation or footshock exposure). Thus, it is important to emphasize that tail-flick stimulation is not the trigger for endocannabinoid mobilization in these studies, and antagonists do not alter basal nociceptive thresholds under testing conditions. A role for CB₂ was not evaluated in studies of endocannabinoid-mediated stimulation-produced analgesia, presumably due to the lack of availability of a CB₂ antagonist at the time the work was conducted [137]. Stress-induced analgesia is also CB₁-mediated; it is blocked by multiple CB₁ antagonists, involves the mobilization of endocannabinoids at supraspinal (2-AG and AEA; [78]) and spinal (2-AG alone; [79]) levels and is enhanced by inhibitors of endocannabinoid deactivation (URB597, AA-5-HT, URB602) or transport (VDM11). The failure of a CB₂ antagonist to block endocannabinoid-mediated stress-induced analgesia in these studies [78] may reflect the absence of a CB₂-mediated component in endocannabinoid-mediated stress analgesia or,

alternately, the failure of the spinally-mediated tail-flick test to detect a CB₂-mediated component of endocannabinoid analgesia. The existence of a cross-tolerance and cross-sensitization between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia suggests that these phenomena are linked by a common mechanism [185]. The development of drugs that inhibit the enzymatic degradation of endocannabinoids (i.e. through inhibition of FAAH or MGL) or their transport has improved our understanding of the functional roles of the endocannabinoid system in modulating pain under physiological conditions.

Effects of exogenous administration of endocannabinoids (focusing on AEA and 2-AG) and their modulation in models of acute, inflammatory and neuropathic pain models are reviewed below. However, one limitation of studies employing exogenous endocannabinoids is that they do not demonstrate that the endogenous ligands play similar roles under physiological conditions.

ACUTE NOCICEPTION

Exogenous administration of endocannabinoids or their modulation via inhibition of endocannabinoid deactivation or uptake can produce antinociception in acute pain models (see Table 1 and Table 2). The magnitude of the observed antinociceptive effect may differ depending upon the assay, the endocannabinoid used and/or the mechanism employed to alter endocannabinoid levels. The *tail flick test* examines the latency for a rodent to “flick” its tail away from a radiant heat source [186], or to remove the tail following immersion in hot water (see Table 1). In this test, the endocannabinoid uptake inhibitors (VDM-11 and UCM707) produce CB₁-mediated antinociception [187] under conditions in which the endocannabinoid system is activated [78]. Exogenous administration of AEA produces antinociception [188–191], although few studies have evaluated whether this effect is mediated by cannabinoid receptors. Several groups have evaluated a CB₁ component in exogenous AEA antinociception [192–194], but other studies have suggested that anandamide produces antinociception through a CB₁-independent mechanism [188,191]. All these studies assessed pharmacological specificity using the CB₁ antagonist/inverse agonist SR141716A antagonist. Thus, it is important to emphasize that SR141716A acts as an inverse agonist at CB₁ receptors and can activate both CB₂ and vanilloid TRPV1 receptors, albeit with low affinity (for review see [195]). Moreover, a role for CB₂ receptors cannot be discounted from contributing to the antinociceptive effects of exogenous administration of AEA, because mediation by CB₂ receptors was not assessed in these studies. MGL (URB602) and FAAH (AA-5-HT, PMSF, PTK, URB597) inhibitors with varying degrees of selectivity also produce antinociceptive effects in the tail flick test [189,196,197], and specifically under conditions in which the endocannabinoid system is activated and basal nociceptive thresholds are not altered by the same treatments ([79,138] for FAAH inhibitors only; [78] for MGL and FAAH inhibitors). In these studies, cannabinoid receptor antagonists directed at CB₁ (AA-5-HT, PTK, URB597 and URB602 [78,79,138]) or at CB₁/CB₂ (URB597 [197]) were used to identify the receptor mechanism underlying these effects. Indeed, studies employing FAAH knockout mice also corroborate the previous results; a CB₁-mediated component is observed in both the tail immersion and hot plate tests under conditions in which both CB₁ and CB₂ antagonists were evaluated [198]. The combination of exogenous AEA with FAAH (ibuprofen, indomethacin, PMSF, URB597) inhibitors also produces antinociception [189,191,196] that is mediated by CB₁ receptors [189,191].

The *hot plate test* involves individually placing rodents on a metal surface typically maintained at 52°C (Range: 52–58°C for these studies) and measures the latency for the rats to exhibit the first sign of pain (i.e. licking the hind paws or jumping) [199] (see Table 2). In this procedure, inhibitors of endocannabinoid uptake (UCM707, OMDM-2, VDM-11) produce

antinociception, although mediation by cannabinoid receptors has not been assessed using competitive antagonists [200,201]. Moreover, exogenous administration of AEA produces an antinociceptive effect in the hotplate test [192,202,203] that seems to be CB₁-mediated [192] (see Table 2). Consistent with this observation, FAAH inhibitors (URB597 and URB532) produce CB₁-mediated antinociception [204]. Endocannabinoid uptake inhibitors (UCM707 and OMDM-1) also potentiate the antinociceptive effect of exogenous anandamide at a dose that did not produce an effect when given alone [200,201]. These observations are consistent with the CB₁-mediated enhancement of endocannabinoid-mediated stress analgesia produced by the uptake inhibitor VDM11 in the tail-flick test [78].

The *plantar test* measures the latency for animals to remove their paws from a radiant heat source that is focused onto the plantar surface of the paw through the floor of a glass platform [205]. In this test, the FAAH inhibitor Compound 17 dose-dependently potentiates the effects of exogenous AEA in the plantar test [206]. Finally, exogenous administration of AEA also produces CB₁-mediated antinociception in the *paw pressure test* [207], assessed using the method of Randall and Selitto [208] (see Table 2). A role for cannabinoid CB₂ receptors in antinociception in otherwise naive animals has been studied in an attempt to optimize the therapeutic potential of cannabinoid analgesic systems. CB₂ agonists show therapeutic potential because they are devoid of the unwanted central side-effects attributed to activation of CB₁ receptors ([124] for a review). However, previous studies assessing responsiveness to acute nociceptive stimulation have either not typically examined the role of CB₂ in mediating effects linked to endocannabinoids (AEA and 2-AG), or have not supported the involvement of CB₂ mechanisms in endogenous analgesia [78]. It is therefore acknowledged that only certain assays (e.g. the plantar test) are likely to be sensitive to detection of CB₂-mediated antinociceptive effects in the absence of inflammation or injury (for review see [124]). Thus, animal models of persistent pain are likely to be differentially sensitive to CB₂-mediated components of cannabinoid antinociception. Thus, manipulation of endocannabinoid accumulation through inhibition of metabolism or reuptake mechanisms may be employed to elucidate a role for cannabinoid CB₂ receptors under conditions of inflammation or injury.

PERSISTENT INFLAMMATORY NOCICEPTION

Cannabinoids produce antinociception in tissue injury models of persistent pain. Indeed, behavioural, electrophysiological and neurochemical studies all support a role for cannabinoid CB₁ and CB₂ receptors in modulating inflammatory nociception (for review see [126]). Effects of exogenous administration of endocannabinoids and/or their modulators (i.e. inhibitors of endocannabinoid uptake or hydrolysis) in different inflammatory pain models (formalin, carrageenan, capsaicin, complete Freund's adjuvant,) is discussed separately because the mechanisms underlying the development and maintenance of distinct inflammatory pain states differs (see Table 3 and Table 4).

The *formalin test* is a well-established model of persistent pain characterized by a transient, biphasic pattern of pain behaviour [209]. The early phase is characterized by acute activation of C and A δ fibers. The late phase involves an inflammatory reaction in peripheral tissue [210], the development of central nervous system sensitization [211,212] and additionally involves activation of primary afferent nociceptors [213]. In the formalin test, endocannabinoid uptake inhibitors (AM404, UCM707, LY2318912, LY2183240, OMDM132) produce antinociception [93,214,215] (see Table 3). These antinociceptive effects are mediated either exclusively by CB₁ receptors [214,215] or by both CB₁ and CB₂ receptors [215]. Exogenous AEA produces CB₁-dependent antinociception in the formalin test [177,216] whereas exogenous 2-AG predominantly produces CB₂-dependent antinociception [217]. The formalin test has also been used to assess antinociceptive effects produced by FAAH inhibitors (MAFP, Flurbiprofen, Ibuprofen, Compound 17, propofol, AA-5-HT, OMDM106, LY2183240 and

others) [178,206,215,216,218–220]. Thus, it is noteworthy that the mechanism of action varies with the compound employed. For example, AA-5-HT [219,220] and LY2183240 produce CB₁-mediated antinociception [215] whereas propofol, a widely used general anesthetic, mediates its antinociceptive effects through activation of CB₁ and CB₂ receptors [221] (see Table 3). FAAH knockout mice also exhibit CB₁-mediated hypoalgesia in both phases of the formalin test [198]. However, the nonsteroidal anti-inflammatory drug ibuprofen produces antinociception in the formalin test that is not related to cannabinoid or TRPV1 receptors [216]. Both CB₁ and CB₂ receptors are implicated in the antinociceptive effects of MGL inhibitors (OMDM169 and URB602) in this test [180,217]. Furthermore, the combination of AEA with nonselective FAAH inhibitors (ibuprofen or rofecoxib) produces an antinociceptive effect [178,216] that is CB₁-mediated [216], whereas the combination of 2-AG with URB602 produces antinociception whose mechanism of action remains to be determined [217].

The *carrageenan model* involves intraplantar injection of the inflammatory agent, carrageenan, which produces paw swelling (edema) and hypersensitivity to mechanical or thermal stimulation [205]. Carrageenan also induces the expression of Fos, a nonspecific marker of neuronal activation, in the lumbar spinal cord [222]. In this model, exogenous administration of anandamide produces antinociception [183,223,224] which is likely to be CB₁-mediated [183] (see Table 4). FAAH inhibitors (URB597 and JNJ-1661010) also produce antinociception in this model ([179,225,226] using URB597; [227] using JNJ-1661010). However, this antinociceptive effect is likely to be independent of CB₁ receptor activation because a CB₁ antagonist failed to reverse the observed antinociceptive effects [179,226]. A role for both CB₂ receptors [179] and peroxisome proliferator-activated receptor- α (PPAR- α) receptors has been implicated in the antinociceptive effects of URB597 in this model [226]. A role for CB₂ but not CB₁ receptors in thermal anti-hyperalgesic effects exhibited by FAAH knockout mice has also been demonstrated; however, neither CB₁ nor CB₂ receptors are implicated in the anti-edemic effects of FAAH^{-/-} mice [198]. Although highly specific MGL inhibitors have only recently been described, MGL-selective inhibitors (URB602 and compound 21) nonetheless exhibit antinociception in this model [228,229; respectively), an effect which involves CB₂ receptors [228]. However, caution must be exerted in interpreting effects of URB602, which also inhibits FAAH, and thus, is unlikely to act as a selective MGL inhibitor following systemic administration.

Capsaicin, the pungent ingredient in hot chili peppers, produces hypersensitivity to mechanical and thermal stimulation as well as spontaneous pain following intradermal administration [230]. Hyperalgesia evoked in *capsaicin model* refers to an increase in pain behavior evoked by suprathreshold stimuli and/or a lowered threshold for pain [230,231]. Only one study has assessed antinociceptive effects following exogenous administration of AEA [202] without investigating the cannabinoid (CB₁ and/or CB₂) receptor mechanism of action (see Table 4). *Complete Freund's adjuvant* (CFA), administered in the plantar hindpaw surface, produces peripheral edema as well as hypersensitivity to mechanical and thermal stimulation in rodents [232–234]. The inflammation appears approximately two hours following injection of complete Freund's adjuvant, produces its maximal effect after six to eight hours and can persist for weeks following injection [233,235]. Exogenous administration of AEA produces antinociception in the CFA model, but this effect does not involve CB₁ receptors [207]. A CB₂ mechanism of action was not investigated in this study, likely due to the lack of available CB₂-selective antagonists at the time of testing. In this model, the antinociceptive effect of the FAAH inhibitor URB597 is mediated by both CB₁ and CB₂ receptors [236]. Furthermore, AM404, an inhibitor of endocannabinoid uptake, produces CB₁-mediated antinociception in the CFA model [214,237] (see Table 4). These observations are consistent with the ability of exogenous anandamide to produce antinociception in other inflammatory pain models (acid

acetic writhing test, kaolin writhing test, and other models) through a CB₁-dependent mechanism [202,238] (see Table 4).

NEUROPATHIC NOCICEPTION

Animal models of neuropathic pain have been developed to mimic symptoms associated with nerve injury observed clinically. Neuropathic pain can be induced by traumatic nerve injury [239–241], toxic insults and metabolic challenges. Pharmacotherapies used to treat neuropathic pain produce inadequate pain relief and/or unwanted side-effects (for review see [124,242]), which reinforce the importance of identifying and validating novel therapeutic approaches which suppress neuropathic pain, including those targeting the endocannabinoid system (see Table 5). The *chronic constriction injury model* is a widely used animal model of neuropathic pain that is produced by loosely placing three constrictive ligatures around the common sciatic nerve [239]. In this model, inhibition of endocannabinoid uptake with AM404 produces antinociceptive effects which are mediated by CB₁ [141,214,243,244] and partially by CB₂ receptors [243]. However, discrepancies between studies are also apparent [214,244] (see Table 5). The endocannabinoid uptake inhibitor VDM11 also produces antinociceptive effects, but involvement of cannabinoid receptors in these effects has not been evaluated [243]. FAAH inhibitors (URB597, AA-5-HT, OL-135) also produce antinociception in the CCI model [219,245]. The FAAH inhibitor URB597 produces antihyperalgesic effects in this model that are CB₁-mediated and partially CB₂-mediated. By contrast, another FAAH inhibitor (AA-5-HT) has been shown to produce antihyperalgesia that is mediated exclusively by CB₁ receptors. No genotype differences in pain behavior were observed between FAAH^{-/-} and wildtype mice subjected to a chronic constriction injury [198]. However, nerve injury may promote adaptive changes in these animals because CCI was found to obliterate the phenotypic hypoalgesia displayed by FAAH^{-/-} mice in the tail immersion and hot plate tests [198].

Pharmacological modulation of endocannabinoid levels also suppresses neuropathic pain behavior in other models of surgically-induced traumatic nerve injury. For example, AM404 produces CB₁-dependent antinociception [237] in a model of unilateral hind limb neuropathy induced by *partial sciatic nerve ligation* (PSNL) [240]. Exogenous administration of anandamide similarly produces CB₁-dependent antinociceptive effects [246,247] whereas the antinociceptive effects of 2-AG, administered via the same route, are CB₁/CB₂ mediated [248] (see Table 5). FAAH inhibitors (URB597, Ibuprofen, Rofecoxib) are also antinociceptive in this model [246,248]. URB597 produces antinociception through a local peripheral mechanism that is mediated by CB₁/CB₂ cannabinoid receptors [248]. However, systemic administration of the same compound does not reliably produce antinociception [236]. Moreover, antinociception produced by local injection of ibuprofen and rofecoxib in the paw does not involve CB₁ or CB₂ cannabinoid receptors [246]. Local administration of URB602 also produces a CB₁/CB₂ antinociception in this model [248]. The combination of FAAH or MGL inhibitors with the exogenous administration of endocannabinoids (AEA or 2-AG) also enhances the antinociceptive effects of the putative endocannabinoid [246,248], but the mechanism of action remains to be determined. The combination of AEA with either ibuprofen or rofecoxib produces antinociception that is mediated exclusively by CB₁ receptors, although the mechanism of action for these other combinations remains to be investigated [246].

Effects of modulation of the endocannabinoid system on neuropathic pain behavior have recently been evaluated using a *spinal nerve ligation model* (SNL). Neuropathic pain was induced by ligating the L5 and L6 spinal nerves according to the procedures described by Kim and Chung [241]. In this model, FAAH inhibitors (URB597, Compound 17, JNJ-1661010 and Compound 34) have been studied exclusively [206,227,249,250] (see Table 5). The antinociceptive effects produced by these agents may involve non-cannabinoid receptor mechanisms (e.g. PPAR- α). However, antinociception produced by URB597 has been shown

to involve CB₁ receptors [249]. Thus, antinociception produced by FAAH/MGL/ endocannabinoid uptake inhibitors are influenced by the compound employed, the animal model used and potentially the level of endocannabinoid tone produced by the injury. Thus, systemic administration of URB597 produces CB₁-mediated enhancements of stress antinociception at doses that do not alter basal nociceptive thresholds in the tail flick test (Table 1). However, systematically administered URB597 produces CB₂-mediated antinociception in the carrageenan model and CB₁/CB₂-mediated antinociception in complete Freund's adjuvant, partial sciatic nerve ligation (local injection) and chronic constriction injury models.

Interpretation of effects of URB602 is more complicated as this compound is not MGL-selective, and can inhibit FAAH; URB602 produces CB₂-mediated antinociception in the carrageenan model (systemic injection) and CB₁/CB₂-mediated antinociception in the formalin test (i.e. following local injection) and partial sciatic nerve ligation (i.e. following local injection) models (see Table 3–Table 5). Thus, effects of URB602 are only likely to be mediated by MGL under conditions in which it is documented that local administration of URB602 increases 2-AG accumulation without altering levels of AEA [78]. Systemic administration of AM404 produces CB₁-mediated antihyperalgesic effects in inflammatory pain models such as complete Freund's adjuvant and formalin models but involves CB₁/CB₂ receptors in the CCI model. Moreover, local exogenous administrations of 2-AG produce CB₂-mediated antinociception in the formalin test and CB₁/CB₂-mediated antinociception in the partial sciatic nerve ligation model. However, local administration of AEA produces CB₁-mediated antinociception in both of these models (see Table 3–Table 5). A local route of agonist administration may unmask CB₂-mediated components in the antinociceptive effects produced by pharmacological inhibitors of endocannabinoid uptake and degradation. However, URB597 produces antinociceptive effects with largely consistent pharmacological specificity following either systemic or local routes of administration. It is also important to emphasize that inhibitors of FAAH elevate levels of fatty-acid amides that do not bind to cannabinoid receptors (e.g. palmitoylethanolamine) and have targets (e.g. PPAR- α) that are distinct from CB₁ and CB₂ receptors. Thus, the contribution of non-cannabinoid receptor mechanisms of action in the *in vivo* pharmacological effects of FAAH and MGL inhibitors must also be considered.

LIMITATIONS

This review focuses on understanding the functional consequences of increasing endocannabinoid accumulation through blockade of endocannabinoid deactivation or transport, with the caveat that many of these agents employed (e.g. FAAH or MGL inhibitors) are not selective for the endocannabinoid system. Moreover, increasing specific endocannabinoids (e.g. anandamide) or fatty-acid amides (e.g. palmitoylethanolamine) can activate other non-cannabinoid receptors (e.g. TRPV1 or PPAR- α , respectively). Entourage effects may also be produced by manipulations that elevate levels of endogenous lipid mediators that do not bind to cannabinoid receptors but, nonetheless, compete for the same enzymes for hydrolysis [251]. Thus, not all effects of these modulators can be attributed to actions at cannabinoid receptors, and assessment of pharmacological specificity is critical for interpretation of *in vivo* actions of any compound. Palmitoylethanolamide (PEA), an endogenous fatty-acid ethanolamide, is an agonist at PPAR- α receptors, but does not bind to cannabinoid receptors [252,253]. However, effects of this compound can nonetheless be blocked by the CB₂ antagonist SR144528 [177]. Inhibition of FAAH by URB597 can also produce antinociceptive effects in inflammatory pain models that are mediated by the activation of PPAR- α receptors [225,226,254]. Synergistic interactions between anandamide and GW7647 (PPAR- α agonist) have been demonstrated in the formalin test [255]. Thus, modulation of the endocannabinoid system by FAAH/MGL/uptake inhibitors and their possible interaction with non-cannabinoid receptors requires further investigation. Even

though increases in endocannabinoid accumulation are produced by inhibition of the degradative enzymes described in this review, differences in selectivity or potency and heretofore uncharacterized off-target effects may complicate interpretation of results. Therefore, the reader should be aware of these limitations when interpreting the results of any specific study.

CONCLUSION

Endocannabinoids modulate pain under physiological conditions. Pharmacological approaches that enhance levels of endocannabinoids by inhibiting enzymes controlling endocannabinoid deactivation or by blocking their reuptake consequently exhibit therapeutic potential. It is clear that the endocannabinoid system is regulated following conditions of injury. Therefore, more work is necessary to better understand the broad consequences of pharmacological approaches that modulate endocannabinoid levels. Inhibition of endocannabinoids deactivation is likely to show a more beneficial and circumscribed spectrum of biological effects compared to direct activation of CB₁ receptors; effects of these inhibitors are limited to sites where endocannabinoids are mobilized under physiological conditions in a stimulation-contingent fashion. Limitations to therapeutic approaches which modulate the endocannabinoid system (e.g. in immunosuppressive diseases) should also be considered when assessing the therapeutic potential of any approach. The impact of long term treatment should be assessed. Multimodal approaches combining modulation of endocannabinoid with other conventional analgesics (e.g. NSAIDs) should also be evaluated for their therapeutic potential. Adjunctive approaches show strong promise for improving the efficacy of existing pharmacotherapies for pain and limiting unwanted side-effect profiles.

Acknowledgments

JG is supported by a Fonds de la Recherche en Santé du Québec (FRSQ) postdoctoral fellowship. AGH is supported by DA021644, DA022478, and DA022702.

ABBREVIATIONS

2-AG	2-arachidonoylglycerol
AA	arachidonic acid
AA-5-HT	N-arachidonoyl serotonin
AEA	anandamide
Ca ²⁺	calcium
CB ₁	cannabinoid receptor 1
CB ₂	cannabinoid receptor 2
CCI	chronic constriction injury
CGRP	calcitonin gene-related peptide
CNS	central nervous system
COX	cyclooxygenase
Δ ⁹ -THC	delta 9-tetrahydrocannabinol
DAG	diacylglycerol
DAGL	diacylglycerol lipase
DR	dorsal raphe

DRG	dorsal root ganglion
ET	endocannabinoid membrane transporter
FAAH	fatty acid amide hydrolase
GABA	γ -amino butyric acid
LOX	lipoxygenase
MAFP	methyl arachidonyl fluorophosphate
MAPK	mitogen-activated protein kinase
MGL	monoacylglycerol lipase
NADA	N-arachidonoyldopamine
NAPE	N-arachidonoyl-phosphatidylethanolamine
NAT	N-acyl transferase
NT	not tested
PAG	periaqueductal gray
PG	prostaglandins
PLC	phospholipase C
PLD	phospholipase D
PMSF	phenylmethylsulfonyl fluoride
PSNL	partial sciatic nerve ligation
PTK	palmitoyltrifluoromethylketone
RVM	rostral ventromedial medulla
SIA	stress-induced analgesia
SNL	spinal nerve ligation
TRPV1	transient receptor potential vanilloid 1

References

1. Abel, EL. Marijuana: The first twelve thousand years. New York: Plenum Press; 1980.
2. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. *Annu. Rev. Med* 2006;57:553–574. [PubMed: 16409166]
3. Zias J, Stark H, Sellman J, Levy R, Werker E, Breuer A, Mechoulam R. Early medical use of cannabis. *Nature* 1993;363:215. [PubMed: 8387642]
4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc* 1964;86:1646–1647.
5. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. *Biochim. Biophys. Acta* 1998;1392:153–175. [PubMed: 9630590]
6. Piomelli D. The endocannabinoid system: a drug discovery perspective. *Curr. Opin. Investig. Drugs* 2005;6:672–679.
7. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev* 2006;58:389–462. [PubMed: 16968947]
8. Wang J, Ueda N. Biology of endocannabinoid synthesis system. *Prostaglandins Other Lipid Mediat.* 2009 in press, PMID: 19126434.

9. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. *Mol. Pharmacol* 1988;34:605–613. [PubMed: 2848184]
10. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990;346:561–564. [PubMed: 2165569]
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 1993;365:61–65. [PubMed: 7689702]
12. Galiègue S, Mary S, Marchand J, Dussosoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem* 1995;232:54–61. [PubMed: 7556170]
13. Howlett AC. Cannabinoid receptor signaling. *Handb. Exp. Pharmacol* 2005;168:53–79. [PubMed: 16596771]
14. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol. Pharmacol* 1995;48:443–450. [PubMed: 7565624]
15. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology* 2004;47:345–358. [PubMed: 15464149]
16. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G, Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. *Biochem. J* 1995;312:637–641. [PubMed: 8526880]
17. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, Calandra B, Le Fur G, Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. *Eur. J. Biochem* 1996;237:704–711. [PubMed: 8647116]
18. Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors : probable involvement of an allosteric modulatory site. *Br. J. Pharmacol* 2002;137:589–596. [PubMed: 12381672]
19. Howlett AC, Mukhopadhyay S. Cellular signal transduction by AEA and 2 arachidonoylglycerol. *Chem. Phys. Lipids* 2000;108:53–70. [PubMed: 11106782]
20. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. *Pharmacol. Ther* 1997;74:129–180. [PubMed: 9336020]
21. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, Singh G, Lees G. Sodium channel inhibition by AEA and synthetic cannabimimetics in brain. *Brain Res* 2003;978:194–204. [PubMed: 12834914]
22. Bouaboula M, Bianchini L, McKenzie FR, Pouyssegur J, Casellas P. Cannabinoid receptor CB1 activates the Na⁺/H⁺ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways. *FEBS Lett* 1999;449:61–65. [PubMed: 10225429]
23. Pertwee RG. Cannabinoid receptors and pain. *Prog. Neurobiol* 2001;63:569–611. [PubMed: 11164622]
24. Herkenham, M. Localization of cannabinoid receptors in brain and periphery. In: Pertwee, RG., editor. *Cannabinoid receptors*. London: Academic Press; 1995. p. 145-166.
25. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *J. Clin. Invest* 2003;112:423–431. [PubMed: 12897210]
26. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. . *Prostaglandins Leukot. Essent. Fatty Acids* 2002;66:101–121. [PubMed: 12052030]
27. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J. Clin. Invest* 2005;115:1298–1305. [PubMed: 15864349]
28. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G,

- Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat. Neurosci* 2007;10:870–879. [PubMed: 17558404]
29. Farquhar-Smith WP, Egertová M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. Cannabinoid CB(1) receptor expression in rat spinal cord. *Mol. Cell. Neurosci* 2000;15:510–521. [PubMed: 10860578]
30. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. *Neuroscience* 1999;92:1171–1175. [PubMed: 10426476]
31. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. *Neuroscience* 1999;90:923–931. [PubMed: 10218792]
32. Lever IJ, Rice AS. Cannabinoids and pain. *Handb. Exp. Pharmacol* 2007;177:265–306. [PubMed: 17087127]
33. Pertwee RG. Cannabinoid pharmacology: the first 66 years. *Br. J. Pharmacol* 2006;147:S163–S171. [PubMed: 16402100]
34. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton JA, Pertwee RG. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. *Eur. J. Pharmacol* 1997;339:53–61. [PubMed: 9450616]
35. Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. *Mol. Neurobiol* 2007;36:26–35. [PubMed: 17952647]
36. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science* 2005;310:329–332. [PubMed: 16224028]
37. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. *Science* 1999;283:401–404. [PubMed: 9888857]
38. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. *Proc. Natl. Acad. Sci. USA* 1999;96:5780–5785. [PubMed: 10318961]
39. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. *Eur. J. Pharmacol* 2000;396:141–149. [PubMed: 10822068]
40. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. *Proc. Natl. Acad. Sci. USA* 1999;96:14136–14141. [PubMed: 10570211]
41. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. *Pharmacol. Ther* 2005;106:133–145. [PubMed: 15866316]
42. Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. *Pharmacol. Ther* 2009;122:83–96. [PubMed: 19248809]
43. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. *Br. J. Pharmacol* 2007;152:825–831. [PubMed: 17704827]
44. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. *Br. J. Pharmacol* 2007;152:1092–1101. [PubMed: 17876302]
45. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. *Pain* 2008;139:225–236. [PubMed: 18502582]

46. Eggerickx D, Deneff JF, Labbe O, Hayashi Y, Refetoff S, Vassart G, Parmentier M, Libert F. Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. *Biochem. J* 1995;309(Pt 3):837–843. [PubMed: 7639700]
47. Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands. *J Cell. Biochem* 2004;92:923–936. [PubMed: 15258916]
48. Uhlenbrock K, Huber J, Ardati A, Busch AE, Kostenis E. Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells. *Cell. Physiol. Biochem* 2003;13:75–84. [PubMed: 12649592]
49. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 1992;258:1946–1949. [PubMed: 1470919]
50. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem. Pharmacol* 1995;50:83–90. [PubMed: 7605349]
51. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem. Biophys. Res. Commun* 1995;215:89–97. [PubMed: 7575630]
52. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2-Arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. *Proc. Natl. Acad. Sci. USA* 2001;98:3662–3665. [PubMed: 11259648]
53. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J. Pharmacol. Exp. Ther* 2002;301:1020–1024. [PubMed: 12023533]
54. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc. Natl. Acad. Sci. USA* 2002;99:8400–8405. [PubMed: 12060783]
55. Ross HR, Gilmore AJ, Connor M. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. *Br. J. Pharmacol.* 2009 PMID:19226289.
56. Bradshaw HB, Walker JM. The expanding field of cannabimimetic and related lipid mediators. *Br. J. Pharmacol* 2005;144:459–465. [PubMed: 15655504]
57. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. *Br. J. Pharmacol* 2004;141:765–774. [PubMed: 14744801]
58. Howlett AC. The cannabinoid receptors. *Prostaglandins Other Lipid Mediat* 2002;68–69:619–631.
59. Reggio PH. Pharmacophores for ligands recognition and activation/inactivation of the cannabinoid receptors. *Curr. Pharm. Des* 2003;9:1607–1633. [PubMed: 12871061]
60. Di Marzo V. Endocannabinoids: synthesis and degradation. *Rev. Physiol. Biochem. Pharmacol* 2006;160:1–24. [PubMed: 18481028]
61. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? *Nat. Rev. Drug Discov* 2008;7:438–455. [PubMed: 18446159]
62. Jin XH, Uyama T, Wang J, Okamoto Y, Tonai T, Ueda N. cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases. *Biochim. Biophys. Acta* 2009;1791:32–38. [PubMed: 19000777]
63. Egertová M, Simon GM, Cravatt BF, Elphick MR. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. *J. Comp. Neurol* 2008;506:604–615. [PubMed: 18067139]
64. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. *J. Biol. Chem* 2004;279:5298–5305. [PubMed: 14634025]
65. Okamoto Y, Wang J, Morishita J, Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. *Chem. Biodivers* 2007;4:1842–1857. [PubMed: 17712822]

66. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acylphosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. *Biochemistry* 2006;45:4720–4726. [PubMed: 16605240]
67. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G. Multiple pathways involved in the biosynthesis of anandamide. *Neuropharmacology* 2008;54:1–7. [PubMed: 17631919]
68. Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. *Protein Pept. Lett* 2007;14:237–246. [PubMed: 17346227]
69. Cocco L, Faenza I, Fiume R, Maria Billi A, Gilmour RS, Manzoli FA. Phosphoinositide-specific phospholipase C (PI-PLC) beta1 and nuclear lipid-dependent signaling. *Biochim. Biophys. Acta* 2006;1761:509–521. [PubMed: 16624616]
70. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J. Cell. Biol* 2003;163:463–468. [PubMed: 14610053]
71. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. *Eur. J. Biochem* 1999;264:258–267. [PubMed: 10447696]
72. Piomelli D. The molecular logic of endocannabinoid signalling. *Nat. Rev. Neurosci* 2003;4:873–884. [PubMed: 14595399]
73. Di Marzo V, Bisogno T, De Petrocellis L. Anandamide : some like it hot. *Trends Pharmacol. Sci* 2001;22:346–349. [PubMed: 11431028]
74. Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. *Chem. Phys. Lipids* 2002;121:3–19. [PubMed: 12505686]
75. Piomelli D. The ligand that came from within. *Trends Pharmacol. Sci* 2001;22:17–19. [PubMed: 11165666]
76. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JD. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). *Br. J. Pharmacol* 2000;129:227–230. [PubMed: 10694225]
77. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 1997;388:773–778. [PubMed: 9285589]
78. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. *Nature* 2005;435:1108–1112. [PubMed: 15973410]
79. Suplita RL 2nd, Gutierrez T, Fegley D, Piomelli D, Hohmann AG. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. *Neuropharmacology* 2006;50:372–379. [PubMed: 16316669]
80. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. *Trends Pharmacol. Sci* 2009;30:79–84. [PubMed: 19070372]
81. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997;389:816–824. [PubMed: 9349813]
82. Di Marzo V, Gobbi G, Szallasi A. Brain TRPV1: a depressing TR(i)P down memory lane? *Trends Pharmacol. Sci* 2008;29:594–600. [PubMed: 18947889]
83. Ross RA. Anandamide and vanilloid TRPV1 receptors. *Br. J. Pharmacol* 2003;140:790–801. [PubMed: 14517174]
84. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. *Curr. Opin. Neurobiol* 2002;12:372–379. [PubMed: 12139983]
85. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. *Neuroscience* 2000;100:685–688. [PubMed: 11036202]
86. Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. *Neuroscience* 2006;139:1405–1415. [PubMed: 16603318]

87. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* 1997;277:1094–1097. [PubMed: 9262477]
88. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. *Nat. Rev. Drug Discov* 2004;3:771–784. [PubMed: 15340387]
89. Hillard CJ, Edgemond WS, Jarraghan A, Campbell WB. Accumulation of *N*-arachidonylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. *J. Neurochem* 1997;69:631–638. [PubMed: 9231721]
90. Hillard CJ, Jarraghan A. Cellular accumulation of anandamide: consensus and controversy. *Br. J. Pharmacol* 2003;140:802–808. [PubMed: 12970089]
91. Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: a critical review. *Life Sci* 2005;77:1584–1604. [PubMed: 15979096]
92. McFarland MJ, Barker EL. Anandamide transport. *Pharmacol. Ther* 2004;104:117–135. [PubMed: 15518883]
93. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D, Iyengar S, Felder CC. Identification of a high-affinity binding site involved in the transport of endocannabinoids. *Proc. Natl. Acad. Sci. USA* 2005;102:17852–17857. [PubMed: 16314570]
94. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. *J. Biol. Chem* 1997;272:3315–3323. [PubMed: 9013571]
95. Hillard CJ, Jarraghan A. The movement of *N*-arachidonylethanolamide (anandamide) across cellular membranes. *Chem. Phys. Lipids* 2000;108:123–134. [PubMed: 11106786]
96. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. *J. Biol. Chem* 2000;275:13484–13492. [PubMed: 10788462]
97. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. *Prog. Neurobiol* 2002;68:247–286. [PubMed: 12498988]
98. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. *Physiol. Rev* 2003;83:1017–1066. [PubMed: 12843414]
99. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. *Nature* 2001;410:588–592. [PubMed: 11279497]
100. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. *Science* 2002;296:678–682. [PubMed: 11976437]
101. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. *Nat. Med* 2008;14:923–930. [PubMed: 18776886]
102. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat. Chem. Biol* 2009;5:37–44. [PubMed: 19029917]
103. Seierstad M, Breitenbucher JG. Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. *J. Med. Chem* 2008;51:7327–7343. [PubMed: 18983142]
104. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* 1996;384:83–87. [PubMed: 8900284]
105. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. *Proc. Natl. Acad. Sci. USA* 1997;94:2238–2242. [PubMed: 9122178]
106. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc. Natl. Acad. Sci. USA* 2002;99:10819–10824. [PubMed: 12136125]
107. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol. Pharmacol* 2004;66:1260–1264. [PubMed: 15272052]

108. Di Marzo V, Fontana A, Cadas H, Schinelli v, Cimino G, Schwartz JC, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* 1994;372:686–691. [PubMed: 7990962]
109. Deutsch DG, Ueda N, Yamamoto S. The fatty acid amide hydrolase (FAAH). *Prostaglandins Leukot. Essent. Fatty Acids* 2002;66:201–210. [PubMed: 12052036]
110. Egertová M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signaling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. *Proc. Biol. Sci* 1998;265:2081–2085. [PubMed: 9842734]
111. Egertová M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and CB (1) cannabinoid receptor expression in the mouse brain : evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. *Neuroscience* 2003;119:481–496. [PubMed: 12770562]
112. Tsou K, Nogueron MI, Muthian S, Sañudo-Pena MC, Hillard CJ, Deutsch DG, Walker JM. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. *Neurosci. Lett* 1998;254:137–140. [PubMed: 10214976]
113. Guindon, J.; Hohmann, AG. *Handbook of Neuroscience for the Neural and Behavioral Sciences. Pain: Mechanisms and Measurement.* Bernston, Gary G.; Cacioppo, John T., editors. New Jersey: John H. Wiley & Sons; 2009. in press
114. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. *FEBS Lett* 1998;422:69–73. [PubMed: 9475172]
115. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscica F, Freund TF. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur. J. Neurosci* 2004;20:441–458. [PubMed: 15233753]
116. Alexander SP, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. *Br. J. Pharmacol* 2007;152:602–623. [PubMed: 17876303]
117. Guindon J, Hohmann AG. A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. *Br. J. Pharmacol* 2008;153:1341–1343. [PubMed: 18297102]
118. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. *Br. J. Pharmacol* 2007;152:624–632. [PubMed: 17704819]
119. Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. *Br. J. Pharmacol* 2008;153:1538–1549. [PubMed: 18297109]
120. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. *Br. J. Pharmacol* 2007;152:594–601. [PubMed: 17618306]
121. Snider NT, Kornilov AM, Kent UM, Hollenberg PF. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. *J. Pharmacol. Exp. Ther* 2007;321:590–597. [PubMed: 17272674]
122. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J. Neurosci* 1991;11:563–583. [PubMed: 1992016]
123. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioural, neurophysiological and neuroanatomical perspectives. *Chem. Phys. Lipids* 2002;121:173–190. [PubMed: 12505699]
124. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. *Br. J. Pharmacol* 2008;153:319–334. [PubMed: 17994113]
125. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. *Prostaglandins Leukot. Essent. Fatty Acids* 2002;66:243–256. [PubMed: 12052040]
126. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. *Handb. Exp. Pharmacol* 2005;168:509–554. [PubMed: 16596786]

127. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. *J. Pharmacol. Exp. Ther* 1991;258:517–523. [PubMed: 1650831]
128. Hohmann AG, Tsou K, Walker JM. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord : comparison with morphine. *Acta. Pharmacol. Sin* 1999;20:1132–1136.
129. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid induced antinociception in rats: evidence supporting periaqueductal gray involvement. *J. Pharmacol. Exp. Ther* 1996;276:585–593. [PubMed: 8632325]
130. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. *Life Sci* 1995;56:2103–2109. [PubMed: 7776838]
131. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. *J. Neurosci* 1996;16:6601–6611. [PubMed: 8815936]
132. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. *Neurosci. Lett* 1998;242:33–36. [PubMed: 9509998]
133. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. *Nature* 1998;395:381–383. [PubMed: 9759727]
134. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. *Nature* 2002;418:530–534. [PubMed: 12152079]
135. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. *Brain Res* 1999;822:237–242. [PubMed: 10082902]
136. Hohmann AG, Martin WJ, Tsou K, Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-212. *Life Sci* 1995;56:2111–2118. [PubMed: 7776839]
137. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. *Proc. Natl. Acad. Sci. USA* 1999;96:12198–12203. [PubMed: 10518599]
138. Suplita RL 2nd, Farthing JN, Gutierrez T, Hohmann AG. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. *Neuropharmacology* 2005;49:1201–1209. [PubMed: 16129456]
139. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. *A.A.P.S. J* 2006;8:E693–E708.
140. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. *Neuropharmacology* 2007;52:415–422. [PubMed: 17011598]
141. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C, Di Marzo V, Mangoni GS, Rossi F, Maione S. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. *Eur. J. Neurosci* 2006;24:2011–2020. [PubMed: 17040473]
142. de Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernandez-Ruiz J, Di Marzo V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. *Biochem. Pharmacol* 2005;70:446–452. [PubMed: 15963472]
143. Smith PB, Martin BR. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia. *Brain Res* 1992;578:8–12. [PubMed: 1324767]
144. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. *J. Pharmacol. Exp. Ther* 1995;272:310–321. [PubMed: 7815346]

145. Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetylevonantradol in the rat. *J. Clin. Pharmacol* 1981;21:334S–340S. [PubMed: 6895380]
146. Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-212. *Neurosci. Lett* 1998;257:119–122. [PubMed: 9870334]
147. Johaneck LM, Simone DA. Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons. *J. Neurophysiol* 2005;93:989–997. [PubMed: 15385593]
148. Sokal DM, Elmes SJR, Kendall DA, Chapman V. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. *Neuropharmacology* 2003;45:404–411. [PubMed: 12871657]
149. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. *J. Neurosci* 1998;18:451–457. [PubMed: 9412521]
150. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212–212 on neuropathic pain behaviors in rats. *Pain* 2003;105:275–283. [PubMed: 14499445]
151. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. *Pain* 2004;109:124–131. [PubMed: 15082134]
152. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. *Eur. J. Neurosci* 2004;20:2311–2320. [PubMed: 15525273]
153. Kelly S, Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. *J. Neurophysiol* 2001;86:3061–3064. [PubMed: 11731561]
154. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. *J. Neurophysiol* 2004;92:3562–3574. [PubMed: 15317842]
155. Strangman NM, Walker JM. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. *J. Neurophysiol* 1999;82:472–477. [PubMed: 10400973]
156. Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. *Pain* 2002;97:11–21. [PubMed: 12031775]
157. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. *Pain* 1999;82:199–205. [PubMed: 10467924]
158. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. *Neuroscience* 2003;119:747–757. [PubMed: 12809695]
159. Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker JM. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. *Neuroscience* 1996;70:791–798. [PubMed: 10627219]
160. Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. *J. Neurophysiol* 1999;81:575–583. [PubMed: 10036261]
161. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. *Neurosci. Lett* 1998;252:13–16. [PubMed: 9756347]
162. Salio C, Doly S, Fischer J, Franzoni MF, Conrath M. Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. *Neurosci. Lett* 2002;329:13–16. [PubMed: 12161251]
163. Sagar DR, Kelly S, Millns PJ, O'Shaughnessy CT, Kendall DA, Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. *Eur. J. Neurosci* 2005;22:371–379. [PubMed: 16045490]

164. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, Molina-Holgado E. The endocannabinoid system is modulated in response to spinal cord injury in rats. *Neurobiol. Dis* 2009;33:57–71. [PubMed: 18930143]
165. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, Scott RH. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. *Neuropharmacology* 2001;40:221–232. [PubMed: 11114401]
166. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. *J. Dermatol. Sci* 2005;38:177–188. [PubMed: 15927811]
167. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. *Neuroscience* 2005;132:1093–1102. [PubMed: 15857713]
168. Farquhar-Smith, WP.; Rice, ASC. Peripheral mechanisms of inflammatory pain: towards the discovery of novel analgesics. In: Adams, AP.; Cashman, JN., editors. *Recent advances in anaesthesia and analgesia*. London: Churchill Livingstone; 2000. p. 41-60.
169. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. *Physiol. Rev* 2006;86:1309–1379. [PubMed: 17015491]
170. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. *Pain* 2006;126:102–114. [PubMed: 16844297]
171. Bridges D, Rice AS, Egertová M, Elphick MR, Winter J, Michael GJ. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. *Neuroscience* 2003;119:803–812. [PubMed: 12809701]
172. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. *Ann. Pharmacother* 2006;40:251–260. [PubMed: 16449552]
173. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J. Clin. Invest* 2003;111:43–50. [PubMed: 12511587]
174. Guindon J, Beaulieu P. The role of the endogenous cannabinoid system in peripheral analgesia. *Current Molecular Pharmacology* 2009;2:134–139. [PubMed: 20021453]
175. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc. Natl. Acad. Sci. USA* 2005;102:3093–3098. [PubMed: 15705714]
176. Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. *Eur. J. Pharmacol* 2000;396:85–92. [PubMed: 10822060]
177. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. *Nature* 1998;394:277–281. [PubMed: 9685157]
178. Guindon J, LoVerme J, De Léan A, Piomelli D, Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? *Eur. J. Pharmacol* 2006;550:68–77. [PubMed: 17027744]
179. Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. *Br. J. Pharmacol* 2005;146:467–476. [PubMed: 16100529]
180. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, Maione S, Di Marzo V, Endocannabinoid Research Group. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. *Biochim. Biophys. Acta* 2009;1791:53–60. [PubMed: 19027877]
181. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE, Steevens CD, Simone DA, Seybold VS. A decrease in anandamide signaling contributes to the maintenance

of cutaneous mechanical hyperalgesia in a model of bone cancer pain. *J. Neurosci* 2008;28:11141–11152. [PubMed: 18971457]

182. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. *Eur. J. Pharmacol* 1997;319:R3–R4. [PubMed: 9042616]
183. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. *Pain* 1998;75:111–119. [PubMed: 9539680]
184. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. *Brain Res* 1998;813:323–328. [PubMed: 9838180]
185. Suplita RL 2nd, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. *Neuropharmacology* 2008;54:161–171. Move so it appears numerically between 184 and 186. [PubMed: 17714742]
186. D'Amour FE, Smith DC. A method for determining the loss of pain sensation. *J. Pharmacol. Exp. Ther* 1941;72:74–79.
187. Hasanein P, Javanmardi K. A potent and selective inhibitor of endocannabinoid uptake, UCM707, potentiates antinociception induced by cholestasis. *Fundam. Clin. Pharmacol* 2008;22:517–522. [PubMed: 18844724]
188. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. *J. Pharmacol. Exp. Ther* 1998;284:1209–1217. [PubMed: 9495885]
189. Haller VL, Stevens DL, Welch SP. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. *Eur. J. Pharmacol* 2008;600:50–58. [PubMed: 18762181]
190. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J. Pharmacol. Exp. Ther* 1994;270:219–227. [PubMed: 8035318]
191. Wiley JL, Razdan RK, Martin BR. Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. *Life Sci* 2006;80:24–35. [PubMed: 16978656]
192. Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. *Behav. Pharmacol* 1999;10:327–331. [PubMed: 10780247]
193. Mason DJ Jr, Lowe J, Welch SP. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. *Eur. J. Pharmacol* 1999;378:237–248. [PubMed: 10493099]
194. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. *J. Pharmacol. Exp. Ther* 1998;286:1301–1308. [PubMed: 9732392]
195. Pertwee RG. Pharmacological actions of cannabinoids. *Handb. Exp. Pharmacol* 2005;168:1–51. [PubMed: 16596770]
196. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. *J. Pharmacol. Exp. Ther* 1997;283:1138–1143. [PubMed: 9399986]
197. Hasanein P, Shahidi S, Komaki A, Mirazi N. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. *Eur. J. Pharmacol* 2008;591:132–135. [PubMed: 18593578]
198. Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. *Pain* 2004;109:319–327. [PubMed: 15157693]
199. van Eick AJ. A change in the response of the mouse in the “hot plate” analgesia-test, owing to a central action of atropine and related compounds. *Acta Physiol. Pharmacol. Neerl* 1967;14:499–500. [PubMed: 5582715]
200. de Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, Viso A, López-Rodríguez ML, Ramos JA. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. *Eur. J. Pharmacol* 2002;449:99–103. [PubMed: 12163112]

201. de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D, Fernandez-Ruiz J, Di Marzo V. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. *Eur. J. Pharmacol* 2004;484:249–257. [PubMed: 14744610]
202. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. *Eur. J. Pharmacol* 2001;419:191–198. [PubMed: 11426841]
203. Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. *J. Pharmacol. Exp. Ther* 1995;273:1235–1244. [PubMed: 7791096]
204. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. *Nat. Med* 2003;9:76–81. [PubMed: 12461523]
205. Hargreaves K, Dubner R, Brown F, Flores C, Joris A. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* 1988;32:77–88. [PubMed: 3340425]
206. Sit SY, Conway C, Bertekap R, Xie K, Bourin C, Burris K, Deng H. Novel inhibitors of fatty acid amide hydrolase. *Bioorg. Med. Chem. Lett* 2007;17:3287–3291. [PubMed: 17459705]
207. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. *Pharmacol. Biochem. Behav* 1998;60:183–191. [PubMed: 9610941]
208. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. *Arch. Int. Pharmacodyn. Ther* 1957;111:409–419. [PubMed: 13471093]
209. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain* 1977;4:161–174. [PubMed: 564014]
210. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. *Pain* 1992;51:5–17. [PubMed: 1454405]
- 211.Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. *Behav. Brain Sci* 1997;20:404–419. discussion 435–513. [PubMed: 10097003]
212. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. *J. Neurosci* 1992;12:3665–3670. [PubMed: 1326610]
213. Puig S, Sorkin LS. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. *Pain* 1996;64:345–355. [PubMed: 8740613]
214. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V, Iacono A, Raso GM, Meli R, Piomelli D, Calignano A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. *J. Pharmacol. Exp. Ther* 2006;317:1365–1371. [PubMed: 16510698]
215. Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. *Br. J. Pharmacol* 2008;155:775–782. [PubMed: 18660824]
216. Guindon J, De Léan A, Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. *Pain* 2006;121:85–93. [PubMed: 16480822]
217. Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. *Br. J. Pharmacol* 2007;150:693–701. [PubMed: 17179944]
218. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Gühring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. *Eur. J. Neurosci* 2003;17:597–604. [PubMed: 12581177]
219. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. *Br. J. Pharmacol* 2007;150:766–781. [PubMed: 17279090]

220. Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, Nalli M, de Novellis V, Woodward DF, Maione S, Di Marzo V. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. *J. Med. Chem* 2007;50:6554–6569. [PubMed: 18027904]
221. Guindon J, LoVerme J, Piomelli D, Beaulieu P. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors. *Anesth. Analg* 2007;104:1563–1569. [PubMed: 17513659]
222. Honoré P, Chapman V, Buritova J, Besson JM. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? *Brain Res* 1995;705:91–96. [PubMed: 8821738]
223. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. *Eur. J. Pharmacol* 1998;345:145–153. [PubMed: 9600630]
224. Tuboly G, Kekesi G, Nagy E, Benedek G, Horvath G. The antinociceptive interaction of anandamide and adenosine at the spinal level. *Pharmacol. Biochem. Behav* 2009;91:374–379. [PubMed: 18760296]
225. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. *Neuropharmacology* 2008;55:85–93. [PubMed: 18534634]
226. Sagar DR, Kendall DA, Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. *Br. J. Pharmacol* 2008;155:1297–1306. [PubMed: 18724387]
227. Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M. Biochemical and biological properties of 4-(3-phenyl-[1,2,4]thiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. *Anesth. Analg* 2009;108:316–329. [PubMed: 19095868]
228. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B. The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. *Br. J. Pharmacol* 2007;152:787–794. [PubMed: 17700715]
229. Magrioti V, Naxakis G, Hadjipavlou-Litina D, Makriyannis A, Kokotos G. A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity. *Bioorg. Med. Chem. Lett* 2008;18:5424–5427. [PubMed: 18819796]
230. Simone DA, Ngeow JY, Putterman GJ, LaMotte RH. Hyperalgesia to heat after intradermal injection of capsaicin. *Brain Res* 1987;418:201–203. [PubMed: 3664271]
231. Gilchrist HD, Allard BL, Simone DA. Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. *Pain* 1996;67:179–188. [PubMed: 8895246]
232. Iadarola MJ, Brady LS, Draisci G, Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. *Pain* 1988;35:313–326. [PubMed: 2906426]
233. Ren K, Dubner R. Inflammatory models of pain and hyperalgesia. *ILAR J* 1999;40:111–118. [PubMed: 11406689]
234. Stein C, Millan MJ, Herz A. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. *Pharmacol. Biochem. Behav* 1988;31:455–51.
235. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. *J. Pharmacol. Exp. Ther* 2003;304:56–62. [PubMed: 12490575]
236. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. *Br. J. Pharmacol* 2006;147:281–288. [PubMed: 16331291]

237. Mitchell VA, Greenwood R, Jayamanne A, Vaughan CW. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. *Clin. Exp. Pharmacol. Physiol* 2007;34:1186–1190. [PubMed: 17880375]
238. Farquhar-Smith WP, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. *Anesthesiology* 2003;99:1391–1401. [PubMed: 14639155]
239. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* 1988;33:87–107. [PubMed: 2837713]
240. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. *Pain* 1990;43:205–218. [PubMed: 1982347]
241. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. *Pain* 1992;50:355–363. [PubMed: 1333581]
242. Guindon J, Walczak JS, Beaulieu P. Recent advances in the pharmacological management of pain. *Drugs* 2007;67:2121–2133. [PubMed: 17927280]
243. Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, Maione S, Rossi F, Giagnoni G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. *Br. J. Pharmacol* 2006;148:1022–1032. [PubMed: 16770320]
244. La Rana G, Russo R, D'Agostino G, Sasso O, Raso GM, Iacono A, Meli R, Piomelli D, Calignano A. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. *Neuropharmacology* 2008;54:521–529. [PubMed: 18093621]
245. Russo R, LoVerme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. *J. Pharmacol. Exp. Ther* 2007;322:236–242. [PubMed: 17412883]
246. Guindon J, Beaulieu P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. *Neuropharmacology* 2006;50:814–823. [PubMed: 16442133]
247. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. *Life Sci* 2003;73:2345–2353. [PubMed: 12941436]
248. Desroches J, Guindon J, Lambert C, Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. *Br. J. Pharmacol* 2008;155:913–924. [PubMed: 18695638]
249. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. *J. Neurosci* 2006;26:13318–13327. [PubMed: 17182782]
250. Timmons A, Seierstad M, Apodaca R, Epperson M, Pippel D, Brown S, Chang L, Scott B, Webb M, Chaplan SR, Breitenbucher JG. Novel ketoazole based inhibitors of fatty acid amide hydrolase (FAAH). *Bioorg. Med. Chem. Lett* 2008;18:2109–2113. [PubMed: 18289847]
251. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur J Pharmacol* 1998;353:23–31. [PubMed: 9721036]
252. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor- α mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol. Pharmacol* 2005;67:15–19. [PubMed: 15465922]
253. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor- α . *J. Pharmacol. Exp. Ther* 2006;319:1051–1061. [PubMed: 16997973]
254. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ. Cannabinoid activation of PPAR α ; a novel neuroprotective mechanism. *Br. J. Pharmacol* 2007;152:734–743. [PubMed: 17906680]

255. Russo R, LoVerme J, La Rana G, D'Agostino G, Sasso O, Calignano A, Piomelli D. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. *Eur. J. Pharmacol* 2007;566:117–119. [PubMed: 17434479]
256. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. *J. Pharmacol. Exp. Ther* 1995;273:1172–1181. [PubMed: 7791088]
257. Raffa RB Jr, Stone DJ, Hipp SJ. Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. *Neurosci. Lett* 1999;263:29–32. [PubMed: 10218903]
258. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. *Br. J. Pharmacol* 2006;147:83–91. [PubMed: 16284631]
259. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. *Pain* 1998;76:189–199. [PubMed: 9696473]




Figure 1.
Formation and inactivation of anandamide and 2-arachidonoylglycerol

Table 1
Antinociceptive effects of modulators of the endocannabinoid system in the tail flick model

Pain Model	Compounds	Mediated by:			References
		Anti-nociception	CB ₁	CB ₂	
Endocannabinoid uptake inhibitors	VDM-11	Yes during SIA	Yes	NT	78
	UCM707	Yes	Yes	NT	187
		Yes	NT	NT	190
		Yes	NT	NT	256
		Yes	NT	NT	203
		Yes	No	NT	188
		Yes	Yes	NT	194
		Yes trend	Yes	NT	192
		Yes	Yes	NT	193
		Yes	NT	NT	257
Exogenous endocannabinoids	AEA	Yes	No	NT	191
		Yes	NT	NT	189
		Yes	NT	NT	224
		Yes	NT	NT	
Tail flick	FAAH inhibitors				
	PMSF	Yes	NT	NT	196
	PTK	Yes during SIA	Yes	NT	138
	AA-5-HT	Yes during SIA	Yes	NT	79, 138
	URB597	Yes during SIA	Yes	NT	78
	Yes during SIA	Yes	NT	79	
	Yes	NT	NT	189	
	Yes	Yes	No	197	

Pain Model	Compounds	Mediated by:			References
		Anti-nociception	CB ₁	CB ₂	
MGL inhibitors	URB602	Yes during SIA Yes during SIA	Yes Yes	NT NT	78 79
	AEA + PMSF	Yes	NT	NT	196
Exogenous Endocannabinoids+ FAAH inhibitors	AEA + Ibuprofen	Yes	Yes	NT	191
	AEA + Indomethacin	Yes	NT	NT	191
	AEA + URB597	Yes	NT	NT	191
		Yes	Yes	No	189

Table 2
Antinociceptive effects of modulators of the endocannabinoid system in acute pain models

Pain Model	Compounds	Mediated by:		Studies
		Anti-nociception	CB ₁ CB ₂	
Hot plate	UCM707	Yes	NT	200
	Endocannabinoid uptake inhibitors	Yes	NT	201
	VDM-11	Yes	NT	201
	O-2093	No	NT	258
Exogenous endocannabinoids	AEA	Yes	NT	203
		Yes	NT	87
		Yes trend	Yes	192
		Yes	NT	202
FAAH inhibitors	URB597	Yes	Yes	204
	URB532	Yes	Yes	204
Endocannabinoid uptake inhibitors + Exogenous endocannabinoids	AM404 + AEA	Yes	NT	87
	UCM707 + AEA	Yes	NT	200
	OMDM-1 + AEA	Yes	NT	201
Plantar	AEA + Compound 17	Yes	NT	206
	Exogenous Endocannabinoids+ FAAH inhibitors			
Paw Pressure Test	AEA	Yes	Yes	207
	Exogenous Endocannabinoids			

Table 3
Antinociceptive effects of modulators of the endocannabinoid system in the formalin model of inflammation

Pain Model	Compounds	Mediated by:			Studies
		Anti-nociception	CB ₁	CB ₂	
Formalin Test	Endocannabinoid uptake inhibitors				
	LY2318912	Yes	NT	NT	93
	UCM707	Yes	NT	NT	214
	AM404	Yes	Yes	No	214
	LY2183240	Yes	Yes	No	215
	OMDM132	Yes	Yes	Yes	215
Exogenous Endocannabinoids					
	AEA	Yes	NT	NT	259
		Yes	Yes	No	177
		Yes	Yes	No	216
	2-AG	Yes	NT	NT	255
		Yes	No	Yes	217
FAAH inhibitors					
	MAPP	Yes	Yes	NT	218
	Flurbiprofen	Yes	Yes	NT	218
	Ibuprofen	Yes	No	No	216
	Rofecoxib	Yes	NT	NT	178
	Propofol	Yes	Yes	Yes	221
	AA-5-HT	Yes	Yes	No	219
	AA-5-HT	Yes	Yes	No	220
	OMDM106	Yes	Yes	NT	220
	Compound 17	Yes	Yes	NT	206
	OMDM119	Yes	No	NT	215
	OMDM122	Yes	No	NT	215

Pain Model	Compounds	Mediated by:			References
		Anti-nociception	CB ₁	CB ₂	
	LY2183240	Yes	Yes	No	215
MGL inhibitors	URB602	Yes	Yes	Yes	217
	OMDM169	Yes	Yes	Yes	180
Exogenous Endocannabinoids + FAAH inhibitors	AEA + Ibuprofen	Yes	Yes	No	216
	AEA + Rofecoxib	Yes	NT	NT	178
Exogenous Endocannabinoids + MGL inhibitors	2-AG + URB602	Yes	NT	NT	217

Table 4
Antinociceptive effects of modulators of the endocannabinoid system in inflammatory pain models

Pain Model	Compounds	Mediated by:			Studies
		Anti-nociception	CB ₁	CB ₂	
Carrageenan	Exogenous Endocannabinoids AEA	Yes	NT	NT	223
		Yes	Yes	NT	183
		Yes	NT	NT	224
FAAH inhibitors	URB597	Yes	No	Yes	179
		Yes	NT	NT	225
		Yes	No	NT	226
		Yes	NT	NT	227
MGL inhibitors	URB602 Compound 21	Yes	No	Yes	228
		Yes	NT	NT	229
Capsaicin	Exogenous Endocannabinoids AEA	Yes	NT	NT	202
		Yes	NT	NT	202
Complete Freund's Adjuvant	Endocannabinoid uptake inhibitors AM404	Yes	Yes	No	214
		Yes trend	NT	NT	237
Exogenous Endocannabinoids	AEA	Yes	No	NT	207
		Yes	No	NT	207
FAAH inhibitors	URB597	Yes	Yes	Yes	236
		Yes	Yes	Yes	236
Acetic Acid Writhing Test	Exogenous Endocannabinoids AEA	Yes	Yes	No	202
		Yes	Yes	No	202

Pain Model	Compounds	Mediated by:			Studies
		Anti-nociception	CB ₁	CB ₂	
	MGL inhibitors Compound 21	Yes	NT	NT	229
Kaolin Writhing Test	Exogenous Endocannabinoids AEA	Yes	Yes	No	202
NGF inflammatory hyperalgesia	Exogenous Endocannabinoids AEA	Yes	Yes	No	238
p-phenyl- quinone stretch test	Exogenous Endocannabinoids AEA	Yes	NT	NT	203
Turpentine bladder inflammation	Exogenous Endocannabinoids AEA	Yes	NT	NT	259

Table 5
Antinociceptive effects of modulators of the endocannabinoid system in neuropathic pain models

Pain Model	Compounds	Mediated by:			References
		Anti-nociception	CB ₁	CB ₂	
CCI	Endocannabinoids uptake inhibitors	AM404	Yes	Yes	243
			Yes	No	214, 244
			Yes	NT	141
		VDM11	Yes	NT	243
	FAAH inhibitors	URB597	Yes	NT	219
			Yes	Yes	245
		AA-5-HT	Yes	Yes	219
		OL-135	Yes	NT	219
			Yes	NT	219
			Yes	NT	219
PSNL	Endocannabinoids uptake inhibitors	AM404	Yes	NT	237
			Yes	NT	237
	Exogenous Endocannabinoids	AEA	Yes	Yes	247
			Yes	No	246
		2-AG	Yes	Yes	248
	FAAH inhibitors	URB 597	No	NT	236
			Yes	Yes	248
		Ibuprofen	Yes	No	246
		Rofecoxib	Yes	No	246
	MGL inhibitors	URB602	Yes	Yes	248
		Yes	Yes	248	

Pain Model	Compounds	Mediated by:			References
		Anti-nociception	CB ₁	CB ₂	
Exogenous Endocannabinoids+ FAAH inhibitors	AEA + Ibuprofen	Yes	Yes	No	246
	AEA + Rofecoxib	Yes	Yes	No	246
	2-AG + URB597	Yes	NT	NT	248
Exogenous Endocannabinoids+ MGL inhibitors	2-AG + URB602	Yes	NT	NT	248
	2-AG +URB597+ URB602	Yes	NT	NT	248
Exogenous Endocannabinoids+ FAAH + MGL inhibitors	URB597	Yes	Yes	NT	249
	Compound 17	Yes	NT	NT	206
	Compound 34	Yes	NT	NT	250
FAAH inhibitors	JNJ-1661010	Yes	NT	NT	227